Skip to main content
. Author manuscript; available in PMC: 2021 Aug 1.
Published in final edited form as: J Hepatol. 2020 Mar 10;73(2):263–276. doi: 10.1016/j.jhep.2020.03.006

Fig. 1. Flowchart of the study design.

Fig. 1.

The summary-level associations were taken from the following genomics consortium: GOLD (Genetics of Obesity-related Liver Disease) for computerized tomography (CT) measured hepatic steatosis[15]; NASH Clinical Research Network (NASH CRN) and Myocardial Infarction Genetics Consortium (MIGen) for biopsy-proven NAFLD[15]; DIAbetes Genetics Replication And Meta-analysis (DIAGRAM) for T2D[16]; Meta-Analyses of Glucose and Insulin-related traits (MAGIC) consortium for glycemic traits including HbA1c[17], fasting glucose[18], fasting insulin[18], fasting proinsulin[19], 2-h glucose[20], homeostatic model assessment of insulin resistance (HOMA-IR)[21] and β-cell function (HOMA-B)[21], and seven insulin secretion and action indices during oral glucose tolerance test (OGTT)[22]; The Genetic Investigation of ANthropometric Traits (GIANT) consortium for body mass index (BMI), waist-hip ratio (WHR), and WHR adjusted for BMI (WHRadjBMI)[23]; The Global Lipids Genetics Consortium (GLGC) for plasma high-density lipoprotein cholesterol (HDL), low-density lipoprotein cholesterol (LDL), total cholesterol (TC), and triglycerides (TG) levels[24].